Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 40c
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $80.50 +2.04%
Revenue Growth %: +89.8%
Financial Fact:
REVENUE: 39.58K
Today's EPS Names:
DTGI, OCCI, MAYS, More
Revenue Growth %: +89.8%
Financial Fact:
REVENUE: 39.58K
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.26), $0.40 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $27.77 million versus the consensus estimate of $53.9 million.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Contango settles $18.75M Lucky Shot obligations for $6.57M
- Tilray Brands acquires HelloMD to expand Canadian cannabis platform
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
